MedTrace Logo

Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan

NCT01397955 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 148

Last updated 2015-04-17

No results posted yet for this study

Summary

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Julina in clinical practice. A total 100 patients will be recruited and followed 3 years since starting Julina administration.

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

E2 transdermal (Julina, BAY86-5435)

Patients in daily life treatment receiving Julina for postmenopausal osteoporosis

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-01-31
Completion
2014-04-30

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01397955 on ClinicalTrials.gov